In addition, STAT3 inhibitors currently being tested in clinical trials33,34 should be used with caution, at least in tumors in which the NOTCH4 pathway and thus HES1 play a protumorigenic role, as in lung adenocarcinoma. Here, STAT3 is linked to lung adenocarcinoma.